Alexion Pharmaceuticals Inc

Find Ratings Reports
ALXN : NASDAQ : Health Care
$142.82 -0.1 | -0.07%
Today's Range: 141.46 - 143.21
Avg. Daily Volume: 1748500.0
09/22/17 - 4:00 PM ET

Financial Analysis


ALEXION PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.52 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 8.24% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)912.0753.12
EBITDA ($mil)389.0300.44
EBIT ($mil)287.0202.65
Net Income ($mil)165.0120.06


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)1444.01180.05
Total Assets ($mil)13489.013029.35
Total Debt ($mil)3248.03446.67
Equity ($mil)8875.08199.34


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin93.5394.48
EBITDA Margin42.6539.89
Operating Margin31.4726.91
Sales Turnover0.250.22
Return on Assets3.860.72
Return on Equity5.871.15
Debt Q2 FY17 Q2 FY16
Current Ratio3.263.59
Debt/Capital0.270.3
Interest Expense24.023.79
Interest Coverage11.968.52


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)224.0224.22
Div / share0.00.0
EPS0.730.53
Book value / share39.6236.57
Institutional Own % n/a n/a
Avg Daily Volume1878586.02969836.0

Valuation


BUY. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 39.88 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.88. Conducting a second comparison, its price-to-book ratio of 3.65 indicates a premium versus the S&P 500 average of 3.10 and a significant discount versus the industry average of 12.14. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ALXN 62.60 Peers 39.88   ALXN 25.66 Peers 27.93

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ALXN is trading at a significant premium to its peers.

 

Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ALXN is trading at a valuation on par to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ALXN 20.40 Peers 25.67   ALXN 0.29 Peers 0.50

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

ALXN is trading at a valuation on par with its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ALXN trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ALXN 3.65 Peers 12.14   ALXN 450.00 Peers 10.47

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ALXN is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ALXN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ALXN 9.49 Peers 94.57   ALXN 20.91 Peers 233.22

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ALXN is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ALXN significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades